Table 6.

Studies investigating benefit of ketosis for cognitive decline among APOE4 carriers

Study	Study Type	Number of Patients	Avg Age	Patient Diagnosis	Test/Measurement Used	Ketogenic intervention	Significant Benefit Observed in Primary Outcome	Benefit in APOE Subgroup Analysis
Morrill 2019	CS	n=1	71	Mild AD	MoCA	Diet	Yes	NA
Stoykovich 2019	CS	n=1	68	Mild AD	MoCA	Diet	Yes	NA
Brown 2018	CS	n=1	38	MCI	MoCA	Diet	Yes	NA
Reger 2004	RCT	n=20	74.7	Probable AD or aMCI	ADAS-Cog, MMSE, SCWIT	Ketogenic agent	Yes	No
Henderson 2009	RCT	n=152	76	Mild to moderate AD	ADAS-Cog, MMSE, ADCS-CGIC	Ketogenic agent	Yes	No
Henderson 2020	RCT	n=413	76	Mild to moderate AD	ADAS-Cog11 ADCS-CGIC	Ketogenic agent	No	No

Abbreviations: CS; Case study, RCT; Randomized Controlled Trial, MCI; Mild Cognitive Impairment, AD; Alzheimer’s Disease, MoCA; Montreal Cognitive Assessment, ADAS-Cog; Alzheimer’s Disease Assessment Scale-Cognitive Subscale, MMSE; mini-mental status examination, SCWIT; Stroop Colour Word Interference Task, ADCS-CGIC; Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change.